Physician profile
Steven L Vicks
NPI 1801904834
$221.88
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.13 · 2020: $25.64 · 2021: $67.81 · 2022: $108.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $53.03 | 2022 | |
| Daiichi Sankyo INC. | $40.34 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $35.97 | 2020-2021 | |
| Abbott Laboratories | $24.13 | 2021 | |
| Amicus Therapeutics, INC. | $20.13 | 2019 | |
| Glaxosmithkline, LLC. | $19.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.83 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $12.44 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Vicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.